Compare WRLD & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | KRRO |
|---|---|---|
| Founded | 1962 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.3M | 187.9M |
| IPO Year | 1994 | 2019 |
| Metric | WRLD | KRRO |
|---|---|---|
| Price | $184.90 | $13.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 45.2K | ★ 77.3K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $585,166,700.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | N/A |
| P/E Ratio | $143.42 | ★ N/A |
| Revenue Growth | 3.60 | ★ 181.46 |
| 52 Week Low | $110.00 | $5.20 |
| 52 Week High | $227.68 | $55.89 |
| Indicator | WRLD | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 59.06 |
| Support Level | $191.81 | $9.76 |
| Resistance Level | $197.42 | $14.42 |
| Average True Range (ATR) | 5.21 | 0.92 |
| MACD | 0.38 | 0.09 |
| Stochastic Oscillator | 71.55 | 67.01 |
World Acceptance Corp operates a small-loan consumer finance (installment loan) business. It offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. The Company generally serves individuals with limited access to other sources of consumer credit such as banks, credit unions, other consumer finance businesses and credit card lenders. The Company also offers income tax return preparation services to its loan customers and other individuals. The traditional installment loan industry is a fragmented segment of the consumer lending industry. The Company has one reportable segment: the consumer finance segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.